Teva Allowed New Mifepristone Claim But Not New Defendant
A California federal judge gave Teva permission to update its antitrust suit accusing Corcept Therapeutics of using patent system abuse, bribes and exclusive dealing to block generic competition to its cortisol...To view the full article, register now.
Already a subscriber? Click here to view full article